Advertisement

PentaVision

Optometric Management

Article

Staging and Practical Management of Diabetic Retinopathy

Changes in the health care landscape reveal an opportunity for an update.

By: STEVEN FERRUCCI, OD, FAAO, BRENDA YEH, OD, FAAO
Optometric Management March 2, 2026 Vol 61, Issue March-April 2026 Page(s): 6-10

Clinical Report: Staging and Management of Diabetic Retinopathy

Overview

Accurate staging of diabetic retinopathy (DR) using the International Clinical Diabetic Retinopathy (ICDR) system is essential for risk assessment and timely referral. Nonproliferative stages require periodic monitoring, while proliferative diabetic retinopathy (PDR) demands urgent specialist intervention. Diabetic macular edema (DME) can occur at any stage and is a leading cause of vision loss, necessitating careful macular evaluation.

Background

Diabetic retinopathy is a progressive microvascular complication of diabetes characterized by retinal capillary damage. The ICDR staging system classifies DR into nonproliferative (NPDR) and proliferative (PDR) forms based on retinal findings such as microaneurysms, hemorrhages, and neovascularization. Early detection and staging enable appropriate monitoring intervals and timely referral to retina specialists for treatment. Diabetic macular edema, a common cause of vision loss, can occur at any stage and requires optical coherence tomography (OCT) for detection.

Data Highlights

DR StageKey FeaturesProgression RiskRecommended Follow-up
Mild NPDR≥1 microaneurysm or hemorrhage5-10% worsen in 1 yearRepeat exam in 1 year
Moderate NPDRMicroaneurysms, hemorrhages, mild cotton wool spots, venous beading, IRMAs16% progress to PDR in 4 yearsRepeat exam in 6 months
Severe NPDR"4-2-1" rule criteria met~50% progress to PDR in 1 yearFollow-up every 2-3 months; consider referral
Very Severe NPDR2 criteria of "4-2-1" met~75% progress to PDR in 1 yearFollow-up every 2-3 months; referral advised
High-risk PDRNeovascularization with hemorrhage or large NVD/NVE50% risk of blindness in 5 years without treatmentRefer within 1-2 days for treatment
DMEMacular thickening/exudation; center-involved or non–center-involvedLeading cause of moderate vision lossCenter-involved: refer within 2-4 weeks; Non-center: monitor every 3-4 months

Key Findings

  • The ICDR system classifies DR into NPDR and PDR, guiding monitoring and referral.
  • Mild and moderate NPDR require annual to semiannual follow-up due to moderate progression risk.
  • Severe and very severe NPDR have high progression rates to PDR, necessitating close monitoring every 2-3 months and specialist referral.
  • PDR with high-risk features requires urgent referral for treatment to prevent blindness.
  • DME can occur at any DR stage and is a major cause of vision loss; OCT is critical for detection and management decisions.
  • GLP-1 receptor agonists like semaglutide may transiently worsen retinopathy during rapid glycemic control but do not increase long-term progression risk.

Clinical Implications

Clinicians should utilize the ICDR staging system to stratify patients by risk and determine appropriate follow-up intervals. Early referral to retina specialists is crucial for severe NPDR, very severe NPDR, and PDR to initiate timely treatment and prevent vision loss. Regular macular evaluation with OCT is essential to detect and manage diabetic macular edema, even in asymptomatic patients.

Conclusion

Accurate staging of diabetic retinopathy using the ICDR system enables effective risk stratification and management. Timely monitoring and referral can reduce progression to vision-threatening stages and improve patient outcomes.

References

  1. Early Treatment Diabetic Retinopathy Study -- DRSS and ICDR staging
  2. SUSTAIN-6 Study 2006 -- Semaglutide and diabetic retinopathy risk
  3. Stevens et al 3-year study -- Semaglutide and retinopathy progression